News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cullinan Therapeutics Inc
(NQ:
CGEM
)
20.16
+0.25 (+1.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics Inc
< Previous
1
2
3
4
Next >
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
December 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Recap: Cullinan Oncology Q3 Earnings
November 08, 2023
Via
Benzinga
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Analyst Ratings for Cullinan Oncology
August 09, 2023
Via
Benzinga
Analyst Ratings for Cullinan Oncology
July 07, 2023
Via
Benzinga
Analyst Expectations for Cullinan Oncology's Future
June 15, 2023
Via
Benzinga
Expert Ratings for Cullinan Oncology
June 15, 2023
Via
Benzinga
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
November 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
October 30, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Cullinan Oncology
May 26, 2023
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
May 22, 2023
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
April 10, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
What 4 Analyst Ratings Have To Say About Cullinan Oncology
March 27, 2023
Via
Benzinga
Cullinan Oncology to Participate in Upcoming Investor Conferences
July 31, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
Why Shares of Cullinan Oncology Jumped This Week
June 09, 2023
The company's presentation at a conference got the attention of analysts and investors.
Via
The Motley Fool
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 25, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 26, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
April 20, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
March 27, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
March 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
February 27, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...
Via
Talk Markets
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
February 13, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.